Abstract
Patients on biologic and targeted therapies have a higher risk of developing life-threatening infectious diseases. Most of these infections can be avoided by a correct prophylactic treatment and a carefully planned follow-up. A thorough medical history before starting treatment is required. The physician must take into account the mechanism of action of the biologic agent and the expected impact on the infection risk. Moreover, the physician should also consider the patient’s underlying diseases, prior and concurrent immunosuppressive treatments, and the patient’s birthplace and countries where he or she has lived. It is important to address all these factors so that biologic and targeted therapies are safely used.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fernandez-Ruiz M, Meije Y, Manuel O, Akan H, Carratala J, Aguado JM, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction). Clin Microbiol Infect. 2018;24(Suppl 2):S2–9.
Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-alpha and beyond. Clin Chest Med. 2019;40(4):721–39.
Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47–55.
Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):S21–40.
Nolfi-Donegan D, Konar M, Vianzon V, MacNeil J, Cooper J, Lurie P, et al. Fatal nongroupable Neisseria meningitidis disease in vaccinated patient receiving eculizumab. Emerg Infect Dis. 2018;24(8)
Crew PE, Abara WE, McCulley L, Waldron PE, Kirkcaldy RD, Weston EJ, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis. 2019;69(4):596–600.
Multani A, Ho DY. JC polyomavirus infection potentiated by biologics. Infect Dis Clin N Am. 2020;34(2):359–88.
Mills EA, Mao-Draayer Y. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird’s eye view. Front Immunol. 2018;9:138.
Grebenciucova E, Berger JR. Progressive multifocal leukoencephalopathy. Neurol Clin. 2018;36(4):739–50.
Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, et al. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol. 2016;23(6):1079–85.
Redelman-Sidi G, Michielin O, Cervera C, Ribi C, Aguado JM, Fernandez-Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect. 2018;24(Suppl 2):S95–S107.
Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernandez-Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24(Suppl 2):S71–82.
Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore). 2010;89(5):308–18.
Ogawa E, Wei MT, Nguyen MH. Hepatitis B virus reactivation potentiated by biologics. Infect Dis Clin N Am. 2020;34(2):341–58.
Ciccullo A, Ponziani FR, Maiolo E, Pallavicini F, Pompili M. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report. Infection. 2019;47(2):313–6.
Quiros S, de la Rosa D, Uranga A, Madero R, Amaro R, Bruguera N, et al. Screening for latent tuberculosis infection in patients who are candidate for biological therapies in Spain? A multidisciplinary survey. Arch Bronconeumol. 2018;54(10):510–7.
Smith MY, Attig B, McNamee L, Eagle T. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union. Int J Tuberc Lung Dis. 2012;16(9):1168–73.
Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319–29.
Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24(Suppl 2):S83–94.
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951–70.
Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol. 2008;27(4):541–2.
Tung Chen Y, Perales C, Lacruz J, Senent L, Salavert M. Visceral leishmaniasis infection during adalimumab therapy: a case report and literature review. Int J Rheum Dis. 2014;17(7):822–4.
Casabianca A, Marchetti M, Zallio F, Feyles E, Concialdi E, Ferroglio E, et al. Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. Infection. 2011;39(4):375–8.
Pitini V, Cascio A, Arrigo C, Altavilla G. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol. 2012;156(1):1.
Haeseleer C, Martiny D, Van Laethem Y, Cantinieaux B, Martin C. Reactivation of Plasmodium infection during a treatment with infliximab: a case report. Int J Infect Dis. 2020;91:101–3.
Vacas AS, Gomez-Santana LV, Torre AC, Galimberti RL. Reactivation of Chagas-Mazza disease during treatment with infliximab. An Bras Dermatol. 2017;92(6):899–900.
Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. J Clin Rheumatol. 2007;13(3):150–2.
Umekita K, Hashiba Y, Kariya Y, Kubo K, Miyauchi S, Aizawa A, et al. The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study. Mod Rheumatol. 2019;29(5):795–801.
Swaminathan N, Vinicius JM, Serrins J. Hemophagocytic lymphohistiocytosis (HLH) in a patient with disseminated histoplasmosis. Case Rep Hematol. 2020;2020:5638262.
Geraghty EM, Ristow B, Gordon SM, Aronowitz P. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis. Clin Infect Dis. 2007;44(10):e82–4.
Norena I, Fernandez-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti-Infect Ther. 2018;16(10):781–91.
Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, Lopez-Velez R, et al. Recommendations for management of endemic diseases and travel medicine in solid-organ transplant recipients and donors: Latin America. Transplantation. 2018;102(2):193–208.
Pierrotti LC, Levi ME, Di Santi SM, Segurado AC, Petersen E. Malaria disease recommendations for solid organ transplant recipients and donors. Transplantation. 2018;102(2S Suppl 2):S16–26.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lopez-Medrano, F., Silva, J.T. (2022). Timeline and Infectious Disease Evaluation of Candidates to New Therapies. In: Cervera, C., Aguado, J.M. (eds) Infectious Complications in Biologic and Targeted Therapies. Springer, Cham. https://doi.org/10.1007/978-3-031-11363-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-031-11363-5_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-11362-8
Online ISBN: 978-3-031-11363-5
eBook Packages: MedicineMedicine (R0)